NeoStem, Inc. Announces Partial Exercise of Underwriters' Over-Allotment Option
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 1,500,000 shares of its common stock, at a price to the public of $0.50 per share, in connection with the Company's recently announced underwritten public offering of 20,000,000 shares of common stock, bringing total gross proceeds from the offering to $10,750,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 1,500,000 shares of its common stock, at a price to the public of $0.50 per share, in connection with the Company's recently announced underwritten public offering of 20,000,000 shares of common stock, bringing total gross proceeds from the offering to $10,750,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Help employers find you! Check out all the jobs and post your resume.